Pilot study of photodynamic diagnosis with 5 aminolevulinic acid for Esophageal Cancer.

Pilot study of photodynamic diagnosis with 5 aminolevulinic acid for Esophageal Cancer. - Pilot study of photodynamic diagnosis with 5 aminolevulinic acid for Esophageal Cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032209

Enrollment

Registered

2018-04-12

Start date

2018-04-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Interventions

Take 5ALA 3-9 hours before the endoscopy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with esophageal cancer Patient scheduled for endoscpic diagnosis.

Exclusion criteria

Exclusion criteria: Pregnant women or possibly breast-feeding patients Patients with photosensitivity, history of porphyria, or family history

Design outcomes

Primary

Measure	Time frame
Optimal time from oral administration of 5 aminolevulinicacid to the photodynamic diagnosis	—

Secondary

Measure	Time frame
Adverse events due to oral administration of 5 aminolevulinicacid and photodynamic diagnostic equipments	—

Countries

Japan

Contacts

Public ContactKenji Kudo

Tokyo Women's Medical Universty Department of Surgery, Institute of Gastroenterology

kudo.ige@twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026